阿司匹林或可作为接受初次全膝关节置换术的癌症患者的合适预防用药
本研究利用全国数据库纳入2012至2022年间接受初次全膝关节置换术且术前1年内诊断有活动性内脏器官恶性肿瘤的患者,将使用阿司匹林进行血栓预防者(n=2,833)与非阿司匹林药物者(n=2,833)按1:1倾向性评分匹配,比较90天医疗与手术并发症。阿司匹林组深静脉血栓(1.9%对3.2%;OR 0.59 [0.4至0.8],P=0.002)和肺栓塞(0.5%对1.1%;OR 0.42 [0.2至0.8],P=0.008)风险显著更低。作者认为阿司匹林或可作为此类患者静脉血栓栓塞预防的合适选择。
要点
- 阿司匹林组深静脉血栓发生率1.9%对非阿司匹林组3.2%(OR 0.59 [0.4至0.8],P=0.002)。
- 阿司匹林组肺栓塞发生率0.5%对非阿司匹林组1.1%(OR 0.42 [0.2至0.8],P=0.008)。
- 阿司匹林组术后急诊就诊率7.9%对非阿司匹林组11.6%(OR 0.65 [0.5至0.8],P<0.001)。
核心结论
- 基于这些发现,阿司匹林或可作为接受初次全膝关节置换术的内脏器官癌症患者静脉血栓栓塞预防的合适选择。
研究设计与样本
- 本研究利用全国数据库识别2012年至2022年间接受初次全膝关节置换术的患者。
- 仅纳入初次全膝关节置换术前1年内有活动性内脏器官恶性肿瘤诊断代码的患者。
- 使用人口统计学数据、内科合并症和术前抗凝使用情况,将因癌症而接受阿司匹林血栓预防的初次全膝关节置换患者(n=2,833)与非阿司匹林药物者(n=2,833)按1:1倾向性评分匹配。
- 证据等级为III级。
主要发现
- 阿司匹林组深静脉血栓发生率为1.9%,非阿司匹林组为3.2%(OR 0.59 [0.4至0.8],P=0.002)。
- 阿司匹林组肺栓塞发生率为0.5%,非阿司匹林组为1.1%(OR 0.42 [0.2至0.8],P=0.008)。
- 阿司匹林组术后急诊就诊率为7.9%,非阿司匹林组为11.6%(OR 0.65 [0.5至0.8],P<0.001)。
关键数值与推荐
- 活动性内脏器官恶性肿瘤定义为初次全膝关节置换术前1年内诊断。
- 比较阿司匹林单药处方者与其他类型化学预防处方者发生90天医疗和手术并发症的比值比(OR)。
临床怎么用
- 作者认为,阿司匹林或可作为接受初次全膝关节置换术的内脏器官癌症患者静脉血栓栓塞预防的合适选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin is the prophylactic agent of choice for venous thromboembolism prevention in low-risk patients undergoing primary total knee arthroplasty (TKA). However, there remains a paucity of data in the literature on the efficacy of aspirin as a mode of chemoprophylaxis in patients who have a diagnosis of cancer. The purpose of this study was to determine the efficacy of aspirin versus other anticoagulant medications in primary TKA patients who had a diagnosis of active visceral organ malignancy within one year of their arthroplasty procedure. METHODS: This study utilized a national database to identify patients who underwent primary TKA between 2012 and 2022. Only patients who had a diagnosis code for active visceral organ malignancy within 1 year before their primary TKA were included. Using demographic data, medical comorbidities, and preoperative anticoagulation use, primary TKA patients who have cancer and were prescribed aspirin for thromboprophylaxis (n = 2,833) were propensity score matched on a 1:1 basis to those who were on non-aspirin medications (n = 2,833). The odds ratios (ORs) for developing 90-day medical and surgical complications were determined for patients prescribed aspirin only, when compared to those prescribed other types of chemoprophylaxis. RESULTS: Patients in the aspirin group had significantly lower odds of developing deep vein thrombosis (1.9 versus 3.2%; OR 0.59 [0.4 to 0.8], P = 0.002) and pulmonary embolism (0.5 versus 1.1%; OR 0.42 [0.2 to 0.8], P = 0.008), when compared to their counterparts in the non-aspirin group. Furthermore, patients prescribed aspirin were significantly less likely to experience an emergency department visit following their procedure (7.9 versus 11.6%; OR 0.65 [0.5 to 0.8], P < 0.001). CONCLUSION: Based on these findings, aspirin may be a suitable option for venous thromboembolism prophylaxis in patients who have visceral organ cancer who are undergoing primary TKA. LEVEL OF EVIDENCE: Level III.
引用
- Tarabichi S, Verhey JT, Braithwaite C, et al. Aspirin May Be a Suitable Prophylaxis for Cancer Patients Undergoing Primary Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 41482102. doi:10.1016/j.arth.2025.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。